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Albuminuria predicting outcome in diabetes: Incidence of mi-
croalbuminuria in Asia–Pacific Rim. Microalbuminuria is not
an unusual finding in the general population, even in individuals
without diabetes, hypertension, or cardiovascular risk factors.
Prevalence studies in the United States, such as NHANES III,
reported an overall incidence of microalbuminuria in 22,244 pa-
tients, with and without diabetes, of 7.8%. In those individuals
with diabetes, the prevalence was 28.8%. Even in patients with-
out diabetes, cardiovascular disease, or abnormal serum creati-
nine levels, the prevalence of microalbuminuria was still 5.1%.
Similarly, a large Dutch study of 41,000 participants demon-
strated a 7% incidence of microalbuminuria. In those individu-
als with diabetes, the microalbuminuria rate was 16%. Thus, in
both the United States and Europe, prevalence studies indicate
that microalbuminuria is not uncommon.
In southeast Asia and the western Pacific, the incidence of
type 2 diabetes is rapidly escalating. It is expected that by 2025
the major prevalence of type 2 diabetes in the world will not be
in North America or Europe but in Asia–Pacific Rim. Conse-
quently, there is great interest in evaluating the incidence of
microalbuminuria in this region. In the Microalbuminuria
Prevalence Study (MAPS) the prevalence of macroalbumin-
uria was noted to be 18.8% and microalbuminuria 39.8% in a
total of 6800 hypertensive diabetic adult patients from 10 Asian
countries.
Thus, there is important evidence that the substantial preva-
lence of microalbuminuria and macroalbuminuria in the Pacific
region indicates an impending pandemic of diabetic cardiovas-
cular and renal disease.
Microalbuminuria appears to correlate with both
cardiovascular and renal events, as well as all-cause
mortality. Clinical investigations have demonstrated a
continuous relationship between level of urinary albumin
excretion and clinical end points in subjects both with and
without diabetes [1]. For this reason, it is of great impor-
tance to develop effective screening programs to identify
microalbuminuria and provide appropriate intervention.
Large prevalence studies have been conducted in both
North America [2] and Europe [3] to evaluate the inci-
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dence of microalbuminuria and albuminuria in patients
with and without diabetes. These studies illustrate an
overall incidence of microalbuminuria of approximately
7%, which is substantially higher in patients with diabetes,
ranging from 16% to 29%. However, there is little infor-
mation on the prevalence of microalbuminuria in patients
who live in southeast Asia. This is a major concern be-
cause the prevalence of type 2 diabetes is escalating at a
rapid rate in these locations and will far exceed that seen
in North America and Europe by 2025.
The purpose of this report is to provide new informa-
tion on microalbuminuria prevalence in Asia.
METHODS
The Microalbuminuria Prevalence Study (MAPS) was
a cross-sectional epidemiologic study designed to assess
the prevalence of microalbuminuria and macroalbumin-
uria among consecutively screened hypertensive type 2
diabetic adult patients in 10 Asian countries [4]. Predic-
tive factors for microalbuminuria and macroalbuminuria
were characterized using a stepwise logistic regression
model.
Patients were initially screened for microalbuminuria
on a first morning void urine using a visual colorimet-
ric semiquantitative urine test strip (Nephur test, Roche
Diagnostics, Mannheim, Germany). If this test was neg-
ative for albumin, detection of microalbuminuria was
performed on the same urine with a second specific semi-
quantitative test strip (Micral test, Roche Diagnostics).
The intensity of the color-produced proportional to the
albumin concentration was visually compared to the ref-
erence chart on the Micral test bottle. A measurement of
20 mg/L or above was considered positive. A within-trial
validation of the Micral test was performed on a subset
of patients and indicated an overall sensitivity of 91.9%
and a specificity of 63.4% in comparison with an immuno-
turbidimetric determination. The overall sensitivity and
specificity of the Micral test was 95% and 80%, respec-
tively. Patients with leukocyte esterase or nitrates indica-
tive of significant bacteria and patients with significant
hematuria (2+ or above on the dip stick) were excluded.
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As a result of this two-step screening, three albuminuric
subgroups were defined: microalbuminuria, macroalbu-
minuria, and normal. Prevalence rates were calculated
with a two-sided 95% confidence interval with a multi-
variate analysis. Links between two qualitative criteria
were assessed by chi-square test, or a Fisher exact test if
the assumptions of the chi-square test were not met. The
best global model of prediction was assessed by a step-
wise logistic regression. The significance level was fixed
at 5%. All analyses were performed using SAS software
version 8.02 (Cary, NC, USA).
RESULTS AND DISCUSSION
In the MAPS study, a total of 6801 patients were re-
cruited from 103 medical centers throughout 10 Asian
countries, including China, Hong Kong, Indonesia,
Korea, Malaysia, Pakistan, Philippines, Singapore,
Taiwan, and Thailand. The majority of the patients were
Chinese (64%). Almost two thirds of the patients had at
least one family member with a history of diabetes, hy-
pertension, cardiovascular, or kidney disease. The preva-
lence of macroalbuminuria was 18.8%, and the preva-
lence of microalbuminuria was 39.8%. Mean systolic
blood pressure was higher in the macroalbuminuria pa-
tients (148.3 mm Hg) compared to microalbuminuria and
normal albuminuric patients: 142.9 and 140.0 mm Hg, re-
spectively. Only 11.6% of patients had their systolic and
diastolic blood pressure below the 130/80 mm Hg tar-
get. The mean age of the patients was 61.1 years, with
a body mass index of 25.5. Angiotensin-converting en-
zyme (ACE) inhibitors (43.9%), calcium channel block-
ers (41.5%), angiotensin receptor blockers (19.2%), and
beta-blockers (24.0%) were the most commonly used
drugs. Only 19.4% of patients were receiving diuretics.
Less than 40% were receiving a lipid-lowering agent. In
the multivariate analysis, the predictive factors for the
presence of microalbuminuria were increasing age, ele-
vated body mass index, systolic blood pressure level, and
ethnic origin (Korean).
Importantly, this study demonstrates a 40% incidence
of microalbuminuria in the Asian Pacific Rim countries.
This is a startling incidence that is substantially greater
than what is seen in North American and European
prevalence studies. Also interesting is that the body mass
index of these patients is not as substantial as that seen
in western countries, suggesting that there may be a dif-
ferent association between the incidence of obesity and
diabetes with microalbuminuria in the Pacific Rim than in
western countries. This high prevalence of microalbumin-
uria raises alarm because it has been well demonstrated
that microalbuminuria is predictive of progressive dete-
rioration of kidney function, and is associated with an in-
creased risk of cardiovascular events and death. The high
prevalence of microalbuminuria and macroalbuminuria
in patients from the Asian Pacific Rim is of substantial
concern and indicates an impending pandemic of dia-
betic, cardiovascular, and renal disease unless appropri-
ate screening techniques and interventional strategies are
utilized.
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